238 related articles for article (PubMed ID: 27175597)
1. Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.
Denoyer D; Pearson HB; Clatworthy SA; Smith ZM; Francis PS; Llanos RM; Volitakis I; Phillips WA; Meggyesy PM; Masaldan S; Cater MA
Oncotarget; 2016 Jun; 7(24):37064-37080. PubMed ID: 27175597
[TBL] [Abstract][Full Text] [Related]
2. Increasing intracellular bioavailable copper selectively targets prostate cancer cells.
Cater MA; Pearson HB; Wolyniec K; Klaver P; Bilandzic M; Paterson BM; Bush AI; Humbert PO; La Fontaine S; Donnelly PS; Haupt Y
ACS Chem Biol; 2013 Jul; 8(7):1621-31. PubMed ID: 23656859
[TBL] [Abstract][Full Text] [Related]
3. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
4. Designing salicylaldehyde isonicotinoyl hydrazones as Cu(II) ionophores with tunable chelation and release of copper for hitting redox Achilles heel of cancer cells.
Ji Y; Dai F; Zhou B
Free Radic Biol Med; 2018 Dec; 129():215-226. PubMed ID: 30240704
[TBL] [Abstract][Full Text] [Related]
5. Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest.
Cho HJ; Lim DY; Kwon GT; Kim JH; Huang Z; Song H; Oh YS; Kang YH; Lee KW; Dong Z; Park JH
Int J Mol Sci; 2016 Feb; 17(2):264. PubMed ID: 26907265
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
7. Glutathione Peroxidase 3 Inhibits Prostate Tumorigenesis in TRAMP Mice.
Chang SN; Lee JM; Oh H; Park JH
Prostate; 2016 Nov; 76(15):1387-98. PubMed ID: 27325372
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
9. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice.
Chang SN; Han J; Abdelkader TS; Kim TH; Lee JM; Song J; Kim KS; Park JH; Park JH
Prostate; 2014 Sep; 74(13):1266-77. PubMed ID: 25053105
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous copper concentrations in cancerous human prostate tissues.
Denoyer D; Clatworthy SA; Masaldan S; Meggyesy PM; Cater MA
Prostate; 2015 Oct; 75(14):1510-7. PubMed ID: 26012532
[TBL] [Abstract][Full Text] [Related]
11. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
13. Copper Ionophores as Novel Antiobesity Therapeutics.
Meggyesy PM; Masaldan S; Clatworthy SAS; Volitakis I; Eyckens DJ; Aston-Mourney K; Cater MA
Molecules; 2020 Oct; 25(21):. PubMed ID: 33120881
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
16. Targeting redox vulnerability of cancer cells by prooxidative intervention of a glutathione-activated Cu(II) pro-ionophore: Hitting three birds with one stone.
Bao XZ; Dai F; Li XR; Zhou B
Free Radic Biol Med; 2018 Aug; 124():342-352. PubMed ID: 29935260
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
Allensworth JL; Evans MK; Bertucci F; Aldrich AJ; Festa RA; Finetti P; Ueno NT; Safi R; McDonnell DP; Thiele DJ; Van Laere S; Devi GR
Mol Oncol; 2015 Jun; 9(6):1155-68. PubMed ID: 25769405
[TBL] [Abstract][Full Text] [Related]
18. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
19. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
20. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
